![]() He launched his hedge fund in 1956 with $105,100 in seed capital. Warren Buffett never mentions this but he is one of the first hedge fund managers who unlocked the secrets of successful stock market investing. And so Becker, do you want to talk about what we’ll be showing at ASH? But elenestinib is going to have a great space in our portfolio, as we think about building that franchise for 10 years and beyond. And so the solution for those patients are truly in the market today. AYVAKIT is really meeting the broad medical needs across the spectrum of SM. As Christie really laid out is elenestinib is positioned to help us maximize the long-term performance of our SM franchise. As we look to the 263 data, could you help us understand exactly what will be presented and your view here on what would be a competitive profile in the context of AYVAKIT but also competitors? Thank you. ![]() Operator: Our next question comes from Salveen Richter with Goldman Sachs. But the bottom line is this opportunity is unfolding exactly as we had expected and we are well on our way to making AYVAKIT blockbuster in SM. And so we see opportunity to continue to expand that through geographic launches by growing the market in the US, et cetera. As Philina said, the dynamics that we see in the US alone based on the market as it sits today get AYVAKIT to a blockbuster status. And there’s - we expect to see very similar trends as we launch globally. And AYVAKIT is really transforming patient lives. The receptivity to the profile has been incredibly positive. And I think Reni your question was kind of higher level regarding the opportunity and how we see it unfolding in the US versus Europe? And what I would say is, I think what the US experience has shown us at this point is that these patients are there. So we are looking forward to approval in Europe. Christie, do you want talk about where we are with that one?Ĭhristy Rossi: Sure. ![]() Kate Haviland: And then just to comment on the EU approval. So in sum, we see a really healthy mix in terms of our prescriber base as well as headroom to continue to grow on that breadth and depth. And secondly, agnostic of specialty we’re seeing that penetration into new prescribers who are just seeing really the deepest - the biggest concentration of SM patients, who have the biggest potential to deepen over time. We saw that big step-up in the number of new prescribers that and importantly, that occurred among, a, the allergists who are important because they tend to see a greater concentration of ISM patients. To your question on the prescriber base we are really pleased with the mix of prescriber base that we’re seeing. We can see that by the vast majority of patients who have started on the 25-milligram dose. So of the 200 patients, I mean, I think the bottom line is the inflection point that we’ve seen in this past quarter is primarily driven by ISM. So maybe Philina, if you could take those. I also think you asked a little bit about European approval and then how do you think about the breadth and depth of prescribing. And as we’ve mentioned before that’s very hard to tease out because of the common diagnosis code but I’ll certainly let Philina continue to provide details there. We - you broke up a little bit there at the end but I think it’s really a question around the patients we added and how can we think about the breakdown between different parts of SM advanced versus ISM. Kate Haviland: Thank you so much for the question, Reni. How many ISM versus SM and would we expect a similar think about Europe and the ultimate approval in Europe should we be thinking about a civil trajectory early on? On the 250 patients that were added, I think you’ve been asked this multiple times, so I’m going to try it a different way. Maybe can you talk a little bit about the penetration in into Alegists versus hemoc kind of how many new physicians have you called. Thanks very much for taking the questions and congratulations on a great quarter. Reni Benjamin: Hey good morning everyone. Operator: Our next question comes from Reni Benjamin with JMP Securities. In addition, to the new patient starts that we expect to continue to drive by increasing both the breadth and the depth of prescribing across our prescriber base. I mean some of the key leading indicators that we’ve emphasized on this call that we see is most important for signaling continued growth, include the number of patients on therapy which we see as a strong predictor of continued revenue, given the potential of these patients to remain on therapy for chronic durations.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |